Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa Plus Chemotherapy as Conversion Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07709767Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 2 trial of retlirafusp alfa in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Tangdu Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07709767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709767.